Laurus Labs – Can Business Transform to Next Level?

If i recall correctly, in March 2023 concall, they said

“10 patients have been dosed under clinical trials (Ph II/III) for r/r Lymphoma / Leukemia by Mar 2023”

So they are guiding FY25. As per my understanding, Phase 2 is for proving the efficacy, while Phase 3 is for deciding the dosage. Also, Phase 3 is administered to much wider number of patients.

So if the drug is to be given to large number of patients, it would translate to orders for Laurus. And once commercialized, order should increase even more.